James Halifax: Psychedelics Showing Strong Signs Despite Stock Losses

TL;DR

Psychedelic stocks have experienced a downturn in the market, but companies are making significant progress in the development of psychedelic medicines.

Transcript

and welcome back to another one of our end of year chats for 2021 this time around we're talking all about psychedelic business i'm brian mcgovern senior editor for the investing news network and with me today joining me to discuss psychedelics is james halifax host of the psychedelic investor james thank you so much well thank you for having me on... Read More

Key Insights

• 💄 Despite the decline in stock prices, many companies are making significant progress in the development of psychedelic medicines.
• 👶 Companies like Cybin and ATAI are introducing new compounds and conducting multiple trials, indicating the industry's potential for growth.
• 👻 Financial stability has been achieved through successful funding rounds, allowing companies to continue their research.
• ✋ Investors in the psychedelic sector need to be aware of the long-term nature of this investment and the high volatility of the stocks.

Questions & Answers

Q: What has been the performance of psychedelic stocks in the market in the last six months?

Psychedelic stocks like Mind Med and Field Trip have seen declines of 40% and 30% respectively in the last six months, indicating a challenging market for these stocks.

Q: What progress have companies made in the development of psychedelic medicines?

Companies like Cybin have introduced new compounds, such as Cyb003, which aims to address the issue of long-lasting effects of psilocybin therapy. ATAI has also initiated multiple trials testing substances like ibogaine, DMT, and a modified version of ketamine.

Q: How have these companies secured funding for their research?

Despite the decline in stock prices, companies like Compass Pathways and Mind Med were able to secure funding when their stocks were at high prices. This financial stability allows them to continue their research into the future.

Q: What should investors in the psychedelic sector be aware of?

Investing in the psychedelic sector requires a long-term perspective, as it may take five or more years for these programs to complete clinical trials. Additionally, the stocks in this industry are highly volatile, with potential for significant declines and increases.

Summary & Key Takeaways

• Psychedelic stocks have seen a decline in the market, with companies like Mind Med and Field Trip down 40% and 30% respectively in the last six months.

• However, many companies are making advancements in the development of psychedelic medicines, such as Cybin's new compound, Cyb003, and ATAI's multiple trials testing different substances.

• These companies have also been able to secure funding for their research, positioning them well for future development.